The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Selecting FLT3 inhibitors in AML: evolving evidence and clinical considerations
Robert Negrin, MD, Stanford University, Stanford, CA, discusses the evolving role of FLT3 inhibitors in acute myeloid leukemia (AML), highlighting how increasing knowledge of FLT3-mutated disease has transformed frontline treatment decisions. Prof. Negrin reviews key considerations when selecting among available FLT3 inhibitors, including toxicity profiles, clinical experience, accessibility, and emerging data favoring more selective agents. He also shares insights into the use of gilteritinib in clinical practice and the need for further comparative studies to guide treatment selection. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
